
    
      This is an open-label study to provide expanded access to TAS-120 prior to its commercial
      availability for patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene
      Rearrangements who have failed standard therapy or who are unable to tolerate standard
      therapy.
    
  